X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES PFIZER SUVEN LIFESCIENCES/
PFIZER
 
P/E (TTM) x 18.5 33.8 54.8% View Chart
P/BV x 3.3 5.4 61.9% View Chart
Dividend Yield % 0.6 0.6 99.9%  

Financials

 SUVEN LIFESCIENCES   PFIZER
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
PFIZER
Mar-18
SUVEN LIFESCIENCES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3382,365 14.3%   
Low Rs1691,625 10.4%   
Sales per share (Unadj.) Rs52.1430.3 12.1%  
Earnings per share (Unadj.) Rs6.878.7 8.7%  
Cash flow per share (Unadj.) Rs8.693.2 9.2%  
Dividends per share (Unadj.) Rs1.5020.00 7.5%  
Dividend yield (eoy) %0.61.0 59.0%  
Book value per share (Unadj.) Rs65.3586.5 11.1%  
Shares outstanding (eoy) m127.2845.75 278.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.94.6 104.9%   
Avg P/E ratio x37.125.3 146.4%  
P/CF ratio (eoy) x29.621.4 138.2%  
Price / Book Value ratio x3.93.4 114.2%  
Dividend payout %22.025.4 86.4%   
Avg Mkt Cap Rs m32,27291,271 35.4%   
No. of employees `0001.12.6 41.1%   
Total wages/salary Rs m6613,143 21.0%   
Avg. sales/employee Rs Th6,132.27,484.8 81.9%   
Avg. wages/employee Rs Th611.11,195.0 51.1%   
Avg. net profit/employee Rs Th803.51,369.1 58.7%   
INCOME DATA
Net Sales Rs m6,63519,685 33.7%  
Other income Rs m2421,143 21.2%   
Total revenues Rs m6,87720,828 33.0%   
Gross profit Rs m1,6045,003 32.1%  
Depreciation Rs m221663 33.4%   
Interest Rs m384 897.6%   
Profit before tax Rs m1,5875,479 29.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,878 38.2%   
Profit after tax Rs m8693,601 24.1%  
Gross profit margin %24.225.4 95.1%  
Effective tax rate %45.234.3 131.9%   
Net profit margin %13.118.3 71.6%  
BALANCE SHEET DATA
Current assets Rs m6,23224,167 25.8%   
Current liabilities Rs m1,4909,544 15.6%   
Net working cap to sales %71.574.3 96.2%  
Current ratio x4.22.5 165.2%  
Inventory Days Days8655 156.9%  
Debtors Days Days8329 287.8%  
Net fixed assets Rs m4,0439,514 42.5%   
Share capital Rs m127458 27.8%   
"Free" reserves Rs m8,18326,375 31.0%   
Net worth Rs m8,31026,832 31.0%   
Long term debt Rs m1825 71.2%   
Total assets Rs m10,38936,900 28.2%  
Interest coverage x43.11,305.5 3.3%   
Debt to equity ratio x00 229.9%  
Sales to assets ratio x0.60.5 119.7%   
Return on assets %8.79.8 89.4%  
Return on equity %10.513.4 78.0%  
Return on capital %19.520.4 95.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62222 25,097.2%   
Fx outflow Rs m1,7991,489 120.9%   
Net fx Rs m3,822-1,466 -260.7%   
CASH FLOW
From Operations Rs m3563,318 10.7%  
From Investments Rs m-279-2,383 11.7%  
From Financial Activity Rs m-225-1,104 20.4%  
Net Cashflow Rs m-148-169 88.0%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.0 7.5 -  
FIIs % 0.0 4.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 23.7 154.0%  
Shareholders   37,287 85,207 43.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 250 Points; Metal & Realty Stocks Drag(12:30 pm)

Share markets in India are presently trading on a negative note. All sectoral indices are trading in red with stocks in the metal sector, realty sector and capital goods sector.

Related Views on News

SUVEN LIFESCIENCES Plunges by 5%; BSE HEALTHCARE Index Down 1.0% (Market Updates)

Jul 24, 2019 | Updated on Jul 24, 2019

SUVEN LIFESCIENCES share price has plunged by 5% and its current market price is Rs 241. The BSE HEALTHCARE is down by 1.0%. The top gainers in the BSE HEALTHCARE Index are TORRENT PHARMA (up 4.2%) and BLISS GVS PHARMA (up 2.3%). The top losers is SUVEN LIFESCIENCES (down 5.1%)..

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

Here's Why This Smallcap Will Beat the Big Autos in the EV Race(Profit Hunter)

Jul 16, 2019

As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 24, 2019 02:05 PM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS